MUC1
Available structures PDB Human UniProt search:PDBeRCSB List of PDB id codes 1SM3,2ACM
Identifiers
Aliases	MUC1, ADMCKD, ADMCKD1, CA 15-3, CD227, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM, mucin 1, cell surface associated, ADTKD2, Ca15-3, Mucin-1
External IDs	OMIM:158340;HomoloGene:136477;GeneCards:MUC1;OMA:MUC1 - orthologs
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1q22 Start 155,185,824bp[1] End 155,192,916bp[1]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in pylorus pancreatic ductal cell nasal epithelium right uterine tube cardia olfactory zone of nasal mucosa lower lobe of lung buccal mucosa cell gastric mucosa palpebral conjunctiva n/a More reference expression data BioGPS More reference expression data
Gene ontology Molecular function protein binding transcription coregulator activity RNA polymerase II cis-regulatory region sequence-specific DNA binding p53 binding Cellular component extracellular region cytoplasm integral component of membrane nucleus Golgi lumen integral component of plasma membrane apical plasma membrane membrane vesicle extracellular exosome extracellular space plasma membrane Biological process positive regulation of histone H4 acetylation regulation of transcription from RNA polymerase II promoter in response to stress DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator negative regulation of cell adhesion mediated by integrin DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator positive regulation of transcription from RNA polymerase II promoter in response to stress O-glycan processing negative regulation of transcription by competitive promoter binding stimulatory C-type lectin receptor signaling pathway cytokine-mediated signaling pathway Sources:Amigo /QuickGO
Orthologs Species Human Mouse Entrez 4582 n/a Ensembl ENSG00000185499 n/a UniProt P15941 Q7Z551 n/a RefSeq (mRNA) NM_001018016 NM_001018017 NM_001018021 NM_001044390 NM_001044391 NM_001044392 NM_001044393 NM_001204285 NM_001204286 NM_001204287 NM_001204288 NM_001204289 NM_001204290 NM_001204291 NM_001204292 NM_001204293 NM_001204294 NM_001204295 NM_001204296 NM_001204297 NM_002456 NM_182741 NM_001371720 n/a RefSeq (protein) NP_001018016 NP_001018017 NP_001037855 NP_001037856 NP_001037857 NP_001037858 NP_001191214 NP_001191215 NP_001191216 NP_001191217 NP_001191218 NP_001191219 NP_001191220 NP_001191221 NP_001191222 NP_001191223 NP_001191224 NP_001191225 NP_001191226 NP_002447 NP_001358649 NP_001191217.1 NP_001191225.1 NP_001037856.1 n/a Location (UCSC) Chr 1: 155.19 – 155.19 Mb n/a PubMed search [2] n/a
Wikidata
View/Edit Human

Mucin short variant S1, also calledpolymorphic epithelial mucin (PEM) orepithelial membrane antigen (EMA), is amucin encoded by theMUC1gene in humans.^[3] Mucin short variant S1 is aglycoprotein with extensiveO-linked glycosylation of its extracellular domain. Mucins line the apical surface of epithelial cells in the lungs, stomach, intestines, eyes and several other organs.^[4] Mucins protect the body from infection bypathogen binding tooligosaccharides in the extracellular domain, preventing the pathogen from reaching the cell surface.^[5] Overexpression of MUC1 is often associated with colon, breast, ovarian, lung and pancreatic cancers.^[6]Joyce Taylor-Papadimitriou identified and characterised the antigen during her work with breast and ovarian tumors.

MUC1 is a member of the mucin family and encodes a membrane bound,glycosylatedphosphoprotein. MUC1 has a core protein mass of 120-225 kDa which increases to 250-500 kDa with glycosylation. It extends 200-500 nm beyond the surface of the cell.^[7]

The protein is anchored to the apical surface of manyepithelia by a transmembrane domain. Beyond the transmembrane domain is a SEA domain that contains a cleavage site for release of the large extracellular domain. The release of mucins is performed bysheddases.^[8] The extracellular domain includes a 20 amino acid variable number tandem repeat (VNTR) domain, with the number of repeats varying from 20 to 120 in different individuals. These repeats are rich in serine, threonine and proline residues which permits heavy o-glycosylation.^[7]

Multiple alternatively spliced transcript variants that encode different isoforms of this gene have been reported, but the full-length nature of only some has been determined.^[9]

MUC1 is cleaved in theendoplasmic reticulum into two pieces, the cytoplasmic tail including the transmembrane domain and the extracellular domain. These domains tightly associate in a non-covalent fashion.^[10] This tight, non-covalent association is not broken by treatment withurea, low pH, high salt or boiling. Treatment withsodium dodecyl sulfate triggers dissociation of the subunits.^[11] The cytoplasmic tail of MUC1 is 72 amino acids long and contains several phosphorylation sites.^[12]

The protein serves a protective function by binding to pathogens^[13] and also functions in a cell signaling capacity.^[12]

Overexpression, aberrant intracellular localization, and changes inglycosylation of this protein have been associated withcarcinomas. e.g. TheCanAgtumour antigen is a novel glycoform of MUC1.^[14] In the cell nucleus, the protein MUC1 regulates the activity of transcription factor complexes that have a documented role in tumor-induced changes of host immunity.^[15]

MUC1 has been shown tointeract with:

• CTNND1,^[16]
• ERBB2,^[17][18]
• GRB2,^[19]
• JUP,^[17] and
• SOS1.^[18][19]

The ability of chemotherapeutic drugs to access the cancer cells is inhibited by the heavy glycosylation in the extracellular domain of MUC1. The glycosylation creates a highly hydrophilic region which prevents hydrophobic chemotherapeutic drugs from passing through. This prevents the drugs from reaching their targets which usually reside within the cell. Similarly, the glycosylation has been shown to bind to growth factors. This allows cancer cells which produce a large amount of MUC1 to concentrate growth factors near their receptors, increasing receptor activity and the growth of cancer cells. MUC1 also prevents the interaction of immune cells with receptors on the cancer cell surface through steric hindrance. This inhibits an anti-tumor immune response.^[4]

MUC1 cytoplasmic tail has been shown to bind top53. This interaction is increased by genotoxic stress. MUC1 and p53 were found to be associated with the p53 response element of thep21 gene promoter. This results in activation of p21 which results in cell cycle arrest. Association of MUC1 with p53 in cancer results in inhibition of p53-mediated apoptosis and promotion of p53-mediated cell cycle arrest.^[20]

Overexpression of MUC1 infibroblasts increased the phosphorylation ofAkt. Phosphorylation of Akt results in phosphorylation ofBcl-2-associated death promoter. This results in dissociation of Bcl-2-associated death promoter withBcl-2 andBcl-xL. Activation was shown to be dependent on the upstream activation ofPI3K. Additionally, MUC1 was shown to increase expression of Bcl-xL. Overexpression of MUC1 in cancer. The presence of free Bcl-2 and Bcl-xL prevents the release ofcytochrome c from mitochondria, thereby preventing apoptosis.^[21] MUC1 cytoplasmic tail is shuttled to the mitochondria through interaction withhsp90. This interaction is induced through phosphorylation of the MUC1 cytoplasmic tail bySrc (gene). Src is activated by the EGF receptor family ligandNeuregulin. The cytoplasmic tail is then inserted into the mitochondrial outer membrane. Localization of MUC1 to the mitochondria prevents the activation of apoptotic mechanisms.^[22]

MUC1 cytoplasmic tail was shown tointeract withBeta-catenin. A SXXXXXSSL motif was identified in MUC1 that is conserved with other beta-catenin binding partners. This interaction was shown to be dependent on cell adhesion.^[23] Studies have demonstrated that MUC1 is phosphorylated on a YEKV motif. Phosphorylation of this site has been demonstrated byLYN through mediation ofinterleukin 7,^[24] Src through mediation of EGFR,^[25][26] andPRKCD.^[27] This interaction is antagonized by degradation of beta-catenin byGSK3B. MUC1 blocks the phosphorylation-dependent degradation of beta-catenin by GSK3B.^[28][29] The result is that increased expression of MUC1 in cancer increases stabilized beta-catenin. This promotes the expression ofvimentin andCDH2. These proteins are associated with a mesenchymal phenotype, characterized by increased motility and invasiveness. In cancer cells, increased expression of MUC1 promotes cancer cell invasion through beta-catenin, resulting in the initiation ofepithelial-mesenchymal transition which promotes the formation of metastases.^[30][31]

CA 27.29 (aka BR 27.29) and CA 15-3 measure differentepitopes of the same protein antigen product of the MUC1 gene seen in breast cancer. CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer.

CA 27.29 levels over 100 U/mL and CA 15-3 levels over 25 U/mL are rare in benign conditions and suggest malignancy.

Usingimmunohistochemistry, MUC1 can be identified in a wide range of secretoryepithelia and theirneoplastic equivalents:^[32]

• It is a marker of various types of cancer (see below).^[32]
• In micropapillary carcinoma of the breast and bladder, MUC1 stains the stroma-facing surface of cell clusters of micropapillary units.^[32]
• It can distinguish systemicanaplastic large cell lymphoma (MUC1 positive) from cutaneous anaplastic large cell lymphoma (usually MUC1 negative).^[32]
• Although other antibodies, such ascytokeratins, are more commonly used for the identification ofmetastatic carcinoma deposits, EMA can be used to distinguishmesothelioma, in which it is restricted to the cell membranes and associatedmicovilli, fromadenocarcinoma, in which it is diffusely spread through thecytoplasm.^[33]

Using MUC1, vaccines are being tested against a type of blood cancer calledmultiple myeloma. The technology could in theory be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors. This method would activate theimmune system by trainingT-cells to search out and destroy cells that display a specific molecule (or marker) of MUC1. MUC1 is found on nearly all epithelial cells, but it is over expressed in cancer cells, and its associated glycans are shorter than those of non-tumor-associated MUC1.^[34]

Because MUC1 is overexpressed (and differently glycosylated) in many cancers it has been investigated as a drug target, e.g. for the MUC1vaccine ONT-10, which has had a phase 1 clinical study.^[35]

• Cluster of differentiation
• List of histologic stains that aid in diagnosis of cutaneous conditions
• Mucin-1

• MUC1+protein,+human at the U.S. National Library of MedicineMedical Subject Headings (MeSH)

This article incorporates text from theUnited States National Library of Medicine, which is in thepublic domain.

• Genes on human chromosome 1
• Clusters of differentiation
• Mucins
• Human proteins

• Articles with short description
• Short description is different from Wikidata
• Wikipedia articles incorporating text from the United States National Library of Medicine